// App-Quantinova.ai

: Cost effectiveness of Fingolimod Compared to Interferon-β1a in the Management of Pediatric-Onset Multiple Sclerosis (POMS) in Canada (P1.2-106)

Researchers

Presenter

  • Hamid Reza Nakhaipour

Principal Investigators

  • Umakanth Vudumula

  • Nagasuman Toram

  • Vivek Khurana

  • Robyn Schecter

  • Daniela Pohl

  • Nicholas Adlard

Medical Centers

  • Novartis Pharma Corp, Basel, Switzerland

  • Novartis Pharmaceuticals Canada Inc Dorval QC Canada

  • Novartis Pharmaceuticals Canada Inc Dorval QC Canada

  • Novartis Healthcare Pvt. Ltd, Hyderabad, India

  • The Children's Hospital of Eastern Ontario, Ottawa, ON, Canada

Locations

  • Switzerland

  • Canada

  • India

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Dermatology

  • Genetic Disorder

Disease

  • Multiple Sclerosis

  • Ectodermal dysplasia-syndactyly syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Fingolimod

  • Interferon

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved